Work

85MO Management of adverse events associated with encorafenib plus cetuximab in patients with BRAF V600E mutant metastatic colorectal cancer (BEACON CRC Study)

Year: 2020

Type: article

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2020.10.105

Authors: C-F. Chiu, Y-M. Yeh, K-H. Yeh, J. Desai, T.J. Price, N. Tebbutt, J. Tabernero, L. Velez, T.L. Trevino, A. Grothey, R. Yaeger, A. Gollerkeri, K. Maharry, S. Kopetz

Institutions: China Medical University Hospital, National Cheng Kung University Hospital, National Taiwan University Hospital, Peter MacCallum Cancer Centre, Queen Elizabeth Hospital, Vall d'Hebron Hospital Universitari, The University of Texas MD Anderson Cancer Center, West Cancer Center, Memorial Sloan Kettering Cancer Center, Array BioPharma (United States)

Language: English

Topic: Colorectal Cancer Treatments and Studies

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funder: Pfizer

OpenAlex ID: W4251761434

FWCI: 0.09

Cites:

Cited by: 1

Related to: 10